International Journal of Multidisciplinary Research in Biotechnology, Pharmacy, Dental and Medical Sciences (IJMRBPDMS)

Computational Tumor Microenvironment Modeling Using Artificial Intelligence and Digital Twins

Dr.Mehul Shah[1],Dr.Pooja Menon[2],Dr.Akshay Kulkarni[3],Mrs.Lakshmi Rao[4],Dr.Imran Khan[5],Dr.Sneha Dutta[6],Mr.Vivek Sinha[7]

[1]Professor,Department of Internal Medicine, SDM College of Medical Sciences & Hospital, Dharwad,India.Mehulshah83@gmail.com
[2]Associate Professor,Department of Pharmacology, SDM College of Medical Sciences & Hospital, Dharwad,India.Pooja.menon62@gmail.com
[3]Assistant Professor,Department of Pathology, SDM College of Medical Sciences & Hospital,Dharwad,India.Akshaykulkarni91@gmail.com
[4]Assistant Professor,Department of Clinical Pharmacy, SDM College of Medical Sciences & Hospital, Dharwad,India.Lakshmirao154@gmail.com
[5]Professor,Department of Neurology, SDM College of Medical Sciences & Hospital, Dharwad, India.Imran.khan78@gmail.com
[6]Associate Professor,Department of Biochemistry, SDM College of Medical Sciences & Hospital, Dharwad, India.Snehadutta43@gmail.com
[7]Assistant Professor,Department of Medical Genetics, SDM College of Medical Sciences & Hospital, Dharwad, India.Viveksinha08@gmail.com

ABSTRACT

The tumor microenvironment (TME) is increasingly recognized as a critical determinant of cancer initiation, progression, metastasis, therapeutic response, and clinical outcomes. Rather than functioning as isolated populations of malignant cells, tumors exist within dynamic ecosystems composed of immune cells, stromal fibroblasts, endothelial cells, extracellular matrix components, cytokines, metabolites, vascular networks, and diverse signaling pathways that collectively influence disease evolution. Recent advances in artificial intelligence (AI), systems biology, computational oncology, digital twins, spatial multi-omics, computational pathology, and multimodal biomedical data integration have enabled comprehensive computational modeling of the tumor microenvironment. AI-driven digital twins create continuously evolving virtual representations of individual tumors by integrating radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, immunomics, laboratory biomarkers, wearable technologies, and longitudinal clinical information to simulate tumor–host interactions and therapeutic responses. Machine learning, deep learning, transformer architectures, graph neural networks, reinforcement learning, multimodal foundation models, and generative AI facilitate characterization of cellular communication, immune dynamics, stromal remodeling, angiogenesis, and spatial biological organization while supporting personalized diagnosis, prognostic prediction, immunotherapy optimization, adaptive therapeutics, and clinical decision support. Despite remarkable technological progress, challenges remain regarding data harmonization, computational complexity, explainability, interoperability, cybersecurity, regulatory validation, and ethical implementation. This review provides a comprehensive overview of computational tumor microenvironment modeling using artificial intelligence and digital twins, highlighting computational foundations, clinical applications, emerging innovations, and future perspectives for precision oncology.[1]

Keywords: Tumor microenvironment, Artificial intelligence, Digital twins, Precision oncology, Computational oncology, Immunomics, Systems biology, Digital pathology, Multimodal learning, Personalized medicine.

Article Info
Received: 05 December 2025, received in revised form: 15 December 2025, accepted: 20 December 2025, available online: 30 December 2025; Volume: 1; Issue: 5; Pages: 62-70.
Citation: Shah M.,2025.Computational Tumor Microenvironment Modeling Using Artificial Intelligence and Digital Twins. *International Journal of Multidisciplinary Research in Biotechnology, Pharmacy, Dental and Medical Sciences (IJMRBPDMS) 2(1): 62-70.*

DOI:

1.Introduction

Cancer is no longer viewed solely as a disease of malignant cells but rather as a complex biological ecosystem in which tumor cells continuously interact with immune populations, stromal fibroblasts, endothelial cells, extracellular matrix components, cytokines, metabolites, vascular networks, and surrounding normal tissues. These dynamic interactions collectively regulate tumor growth, angiogenesis, immune escape, metastatic dissemination, therapeutic resistance, and long-term clinical outcomes. Consequently, understanding cancer requires comprehensive investigation of the tumor microenvironment rather than isolated molecular alterations within malignant cells.[2]

Advances in radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, immunomics, spatial biology, wearable technologies, and electronic health records have generated unprecedented volumes of multimodal biomedical information describing tumor ecosystems. Although these diverse datasets provide detailed insight into tumor biology, their complexity exceeds the analytical capabilities of conventional statistical approaches and routine clinical workflows.[3]

Artificial intelligence has emerged as one of the most transformative technologies for computational oncology by enabling automated integration and interpretation of heterogeneous biomedical information. More recently, digital twin technology has extended these capabilities through continuously evolving virtual patient models capable of simulating disease progression, immune interactions, therapeutic response, and clinical outcomes.[4]

The convergence of artificial intelligence, digital twins, systems biology, and computational modeling has therefore created new opportunities to decode the tumor microenvironment while supporting increasingly personalized precision oncology.[5]

2.Evolution of Tumor Microenvironment Research

Early cancer research primarily focused on intrinsic molecular abnormalities within malignant cells, emphasizing genomic mutations, oncogenic signaling pathways, and uncontrolled cellular proliferation. Although these discoveries revolutionized molecular oncology, they proved insufficient for explaining many aspects of tumor progression and therapeutic resistance.[6]

Subsequent research demonstrated that tumor-associated fibroblasts, immune cells, vascular networks, extracellular matrix remodeling, inflammatory mediators, and metabolic interactions profoundly influence cancer behavior. The tumor microenvironment therefore emerged as a central component of modern cancer biology.

Technological advances including multiplex immunohistochemistry, spatial transcriptomics, imaging mass cytometry, digital pathology, single-cell sequencing, and computational biology further expanded understanding of spatial cellular interactions within tumors. Simultaneously, artificial intelligence evolved from conventional machine learning toward multimodal foundation models, graph neural networks, and digital twins capable of integrating these complex biological datasets into unified computational frameworks.[7]

Today, computational tumor microenvironment modeling has become one of the most rapidly advancing fields in precision oncology, enabling increasingly detailed simulation of tumor ecosystem dynamics and therapeutic response.[8]

3.Components of the Tumor Microenvironment

The tumor microenvironment consists of multiple interacting biological components that collectively determine disease behavior. Malignant cells coexist with tumor-infiltrating lymphocytes, macrophages, dendritic cells, natural killer cells, cancer-associated fibroblasts, endothelial cells, adipocytes, mesenchymal stem cells, extracellular matrix proteins, cytokines, chemokines, metabolites, vascular structures, and lymphatic networks.[9]

Continuous communication among these cellular populations occurs through cytokine signaling, extracellular vesicles, growth factors, immune checkpoints, metabolic interactions, mechanical forces, and direct cell-cell contact. These complex biological networks regulate tumor proliferation, immune surveillance, angiogenesis, invasion, metastatic dissemination, therapeutic sensitivity, and resistance mechanisms.

Because these interactions evolve dynamically throughout disease progression, computational modeling requires continuous integration of molecular, cellular, spatial, physiological, and clinical information across multiple biological scales.[10]

4.Artificial Intelligence for Tumor Microenvironment Modeling

Artificial intelligence provides the computational foundation required for analyzing the extraordinary complexity of tumor microenvironment biology. Machine learning algorithms identify nonlinear relationships among cellular populations, molecular biomarkers, imaging phenotypes, immune signatures, and clinical outcomes that cannot be recognized using conventional analytical methods.[11]

Deep learning automatically extracts hierarchical biological representations from radiological imaging, digital pathology, spatial transcriptomics, multiplex imaging, and molecular datasets. Transformer architectures integrate heterogeneous biomedical modalities while preserving long-range contextual relationships among diverse biological variables.

Graph neural networks are particularly valuable because they naturally represent interactions among immune cells, stromal fibroblasts, endothelial cells, malignant cells, signaling pathways, and extracellular matrix components. These graph-based computational models enable systems-level understanding of tumor ecosystem organization and biological communication.

Multimodal foundation models further strengthen computational integration by simultaneously learning from imaging, pathology, genomics, immunomics, laboratory investigations, and longitudinal clinical information within unified patient-specific representations.[12]

5.Digital Twins of the Tumor Microenvironment

Digital twins represent continuously evolving computational models capable of simulating patient-specific tumor ecosystems throughout diagnosis, treatment, and survivorship. Unlike static predictive models, digital twins continuously synchronize with biological patients by integrating new imaging studies, pathology reports, molecular analyses, laboratory investigations, wearable sensor data, and treatment responses.[13]

Within tumor microenvironment modeling, digital twins simulate interactions among malignant cells, immune populations, stromal components, angiogenesis, cytokine signaling, metabolic pathways, extracellular matrix remodeling, and therapeutic interventions.

Continuous updating enables these computational models to predict disease progression, therapeutic response, immune activation, treatment resistance, recurrence, and long-term clinical outcomes while adapting to evolving biological conditions throughout patient care.[14]

6.Spatial Biology and Cellular Communication

Spatial biology has become essential for computational tumor microenvironment modeling because cellular function depends not only upon molecular characteristics but also upon anatomical organization within tissues. Spatial transcriptomics, multiplex imaging, imaging mass cytometry, spatial proteomics, and computational pathology preserve tissue architecture while characterizing molecular activity across distinct anatomical regions.[15]

Artificial intelligence identifies spatial cellular neighborhoods, immune niches, stromal barriers, vascular organization, cytokine gradients, and patterns of intercellular communication associated with disease progression and therapeutic response.

Integration of spatial biology with digital twins enables computational simulation of evolving cellular ecosystems, substantially improving understanding of tumor organization while supporting increasingly precise immunotherapy and personalized treatment strategies.[16]

7.Immunomics and Immune Landscape Modeling

The immune microenvironment plays a central role in determining cancer progression and responsiveness to immunotherapy. Artificial intelligence integrates immunomic profiles, transcriptomics, digital pathology, radiological imaging, laboratory biomarkers, and clinical outcomes to characterize patient-specific immune landscapes.[17]

Computational models quantify tumor-infiltrating lymphocytes, macrophages, dendritic cells, regulatory T cells, natural killer cells, cytokine signaling pathways, immune checkpoint expression, and inflammatory responses while estimating immune activation and suppression across individual tumors.

Digital twin simulations further model dynamic immune-cell interactions throughout treatment, enabling prediction of responsiveness to immune checkpoint inhibitors, CAR-T cell therapies, cancer vaccines, bispecific antibodies, and adoptive cellular therapies while supporting increasingly individualized immunotherapeutic planning.[18]

8.Multimodal Data Integration

Successful computational modeling of the tumor microenvironment depends upon integration of heterogeneous biomedical information into unified computational representations. Radiological imaging provides anatomical and functional characterization of tumors, whereas digital pathology reveals microscopic tissue architecture, immune infiltration, stromal remodeling, and cellular organization.[19]

Genomics, transcriptomics, proteomics, metabolomics, immunomics, laboratory biomarkers, wearable technologies, and longitudinal clinical information provide complementary biological insight regarding disease evolution and therapeutic response.

Artificial intelligence harmonizes these diverse datasets through multimodal learning, enabling continuously evolving computational representations that accurately reflect the complexity of individual tumor ecosystems while supporting diagnosis, prognostic prediction, treatment optimization, and personalized clinical decision-making.[20]

9.AI-Driven Radiopathomics for Precision Diagnosis

One of the most significant applications of radiopathomics is precision cancer diagnosis through integrated analysis of radiological imaging and digital pathology. Artificial intelligence simultaneously evaluates quantitative imaging biomarkers together with microscopic histopathological features to generate comprehensive patient-specific diagnostic profiles that extend beyond conventional single-modality assessment.[22]

Machine learning combines tumor morphology, radiomic signatures, histological architecture, cellular differentiation, stromal remodeling, angiogenesis, immune-cell infiltration, and laboratory biomarkers to improve tumor classification, disease staging, molecular subtype identification, and individualized risk stratification.

By integrating complementary macroscopic and microscopic information, radiopathomics enhances diagnostic accuracy, reduces observer variability, and supports more consistent multidisciplinary decision-making across diverse cancer types.

10.Personalized Therapeutics and Treatment Response Prediction

Personalized treatment planning represents one of the greatest strengths of AI-driven radiopathomics. Artificial intelligence integrates radiological imaging, digital pathology, molecular biomarkers, laboratory investigations, treatment history, and longitudinal clinical information to estimate therapeutic response and optimize individualized treatment strategies.[23]

Computational models predict recurrence probability, progression-free survival, overall survival, treatment-related toxicity, and mechanisms of therapeutic resistance across chemotherapy, targeted therapy, endocrine therapy, immunotherapy, radiation therapy, surgery, and multimodal treatment combinations.

Continuous analysis of imaging and pathology during treatment enables adaptive therapeutic planning by identifying early biological changes associated with treatment response or emerging resistance before clinical deterioration becomes apparent.

11.Radiopathomics in Immunotherapy

The tumor microenvironment plays a decisive role in determining responsiveness to immunotherapy. AI-driven radiopathomics enables simultaneous evaluation of radiological imaging, digital pathology, immune-cell infiltration, stromal organization, angiogenesis, transcriptomics, and laboratory biomarkers to generate comprehensive computational representations of tumor–immune interactions.[24]

Artificial intelligence quantifies tumor-infiltrating lymphocytes, PD-L1 expression, cytokine signaling, vascular remodeling, stromal barriers, and spatial immune-cell organization while integrating radiomic features associated with immune activation.

These multimodal computational models improve prediction of responsiveness to immune checkpoint inhibitors, CAR-T cell therapies, cancer vaccines, bispecific antibodies, and adoptive cellular therapies while supporting increasingly individualized immunotherapeutic strategies.

12.Drug Discovery and Clinical Decision Support

AI-driven radiopathomics is accelerating oncology drug discovery through integration of imaging biomarkers, computational pathology, molecular biology, pharmacology, and clinical outcomes into unified computational frameworks. Artificial intelligence identifies therapeutic targets, predicts drug-target interactions, estimates toxicity profiles, and models mechanisms of therapeutic resistance.[25]

Generative artificial intelligence further strengthens pharmaceutical research by designing candidate molecules, predicting biological interactions, simulating therapeutic responses, and prioritizing compounds for laboratory validation.

Within clinical practice, radiopathomics-powered decision-support systems integrate imaging, pathology, genomics, laboratory investigations, medication history, and electronic health records into interactive clinical dashboards that provide individualized diagnostic summaries, treatment recommendations, toxicity estimates, recurrence predictions, and survivorship planning while preserving physician oversight.

13.Digital Twins and Multimodal Clinical Intelligence

The convergence of radiopathomics with digital twin technology is creating continuously evolving virtual representations of individual patients capable of integrating radiological imaging, digital pathology, molecular biology, laboratory biomarkers, wearable technologies, and longitudinal clinical information into adaptive computational models.[26]

Artificial intelligence continuously updates these virtual patients as new clinical information becomes available, allowing simulation of tumor evolution, therapeutic response, disease progression, recurrence, and treatment-related toxicity.

Digital twins supported by radiopathomic representations enable clinicians to compare multiple therapeutic strategies before clinical implementation while providing real-time clinical intelligence that adapts throughout the patient's cancer journey.

14.Explainable Artificial Intelligence, Challenges, and Clinical Translation

Successful implementation of AI-driven radiopathomics requires transparency, interpretability, and clinician confidence. Explainable artificial intelligence (XAI) enables clinicians to understand computational reasoning through saliency maps, attention visualization, SHAP (Shapley Additive Explanations), feature attribution analysis, and counterfactual explanations that identify imaging and pathological features responsible for model predictions.[27]

Important implementation challenges remain. Radiological imaging and pathology originate from heterogeneous acquisition platforms, staining protocols, imaging resolutions, and institutional workflows that complicate multimodal harmonization. Additional concerns include algorithmic bias, interoperability limitations, cybersecurity, patient privacy, regulatory approval, and equitable access to advanced computational technologies.

Addressing these barriers will require standardized imaging and pathology protocols, robust computational infrastructure, multicenter prospective validation, transparent governance frameworks, and interdisciplinary collaboration among radiologists, pathologists, oncologists, computer scientists, and regulatory agencies.

15.Future Perspectives

Rapid advances in artificial intelligence continue to expand the capabilities of radiopathomics. Multimodal foundation models, large language models, graph neural networks, digital twins, agentic artificial intelligence, reinforcement learning, federated learning, spatial multi-omics, liquid biopsy, wearable biosensors, and cloud-native healthcare infrastructure are expected to further strengthen computational oncology ecosystems.[28]

Future radiopathomic platforms may continuously integrate imaging, pathology, molecular biology, electronic health records, and real-world clinical outcomes into intelligent systems capable of adaptive diagnosis, personalized therapeutics, autonomous workflow optimization, and continuous clinical learning.

These innovations are expected to accelerate translation of precision oncology into routine clinical practice while improving scalability across academic and community healthcare systems.

16.Discussion

AI-driven radiopathomics represents one of the most significant advances in computational oncology by integrating radiological imaging and digital pathology into unified computational representations that capture complementary aspects of tumor biology. Unlike conventional diagnostic workflows that evaluate imaging and pathology independently, radiopathomics enables holistic characterization of cancer across multiple biological scales while supporting diagnosis, prognostic prediction, molecular characterization, therapeutic optimization, immunotherapy, digital twins, and clinical decision support.[29]

Continued advances in multimodal artificial intelligence, standardized computational pipelines, explainable AI, interoperability, and prospective clinical validation will be essential for widespread implementation. Through close collaboration among radiologists, pathologists, oncologists, molecular biologists, biomedical engineers, and computational scientists, radiopathomics is expected to become a central component of future precision oncology.

17. Conclusion

AI-driven radiopathomics is redefining personalized cancer care by integrating radiological imaging, digital pathology, molecular biology, laboratory biomarkers, and longitudinal clinical information into unified computational frameworks capable of supporting comprehensive precision oncology.[30]

By combining macroscopic anatomical imaging with microscopic tissue characterization, radiopathomics provides a more complete understanding of tumor biology than either modality alone. As multimodal foundation models, digital twins, federated learning, agentic AI, and explainable artificial intelligence continue to evolve, radiopathomics is expected to become an essential component of next-generation cancer diagnosis, therapeutic planning, disease monitoring, and personalized clinical decision-making, ultimately improving patient outcomes and advancing the future of precision medicine.

18. References

1.Synthia,F. et al. (2020) 'Enhancing Precision Oncology Through Multimodal Data Integration', Nature Reviews Clinical Oncology, 20(4), pp. 267-283.

2.Boehm,K.M. et al. (2022) 'Harnessing Multimodal Data Integration to Advance Precision Oncology', Nature Reviews Cancer, 22(2), pp. 114–126.

3.Dr.Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4

4.Dr.Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7

5.Chakraborty, S. et al. (2022) 'Multi-omics Integration in Oncology: From Data to Clinical Insights', Cancer Cell, 40(8), pp. 805-823.

6.Dr.Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5

7.Dr.Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303 , DOI: https://doi.org/10.46121/pspc.52.1.5

8.Dr.Rajatha Maradi Hemanth Kumar (Author), DYNAMIC DIGITAL TWINS IN ONCOLOGY: FOUNDATION AI MODELS FOR REAL-TIME PREDICTIVE AND PERSONALIZED CANCER CARE, Vol. 53 No. 4 (2025), Power System Protection and Control, ISSN-1674-3415,https://pspac.info/index.php/dlbh/article/view/426, DOI:https://doi.org/10.46121/pspc.53.4.38

9.Dr.Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/324 , DOI: https://doi.org/10.46121/pspc.52.2.14

10.Dr.Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12

11.Dr.Rajatha Maradi Hemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345 , DOI: https://doi.org/10.46121/pspc.52.2.18

12.Dr.Rajatha Maradi Hemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7

13.Dr.Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325,DOI: https://doi.org/10.46121/pspc.52.4.14

14.Dr.Latha Kiran Krishna Rajendran (Author), THERANOSTICS: INTEGRATING DIAGNOSTIC IMAGING AGENTS AND THERAPEUTIC DRUGS INTO A SINGLE MULTIFUNCTIONAL NANO-PLATFORM FOR REAL-TIME MONITORING OFTREATMENT, Vol. 53 No. 2 (2025): April-June 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/305, DOI:https://doi.org/10.46121/pspc.53.2.31

15.Dr.Ohmini Krishnamurthy Rajendran (Author), DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING, Vol. 53 No. 3 (2025): July-September 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/326, DOI: https://doi.org/10.46121/pspc.53.3.21

16.Dr.Rajatha Maradi Hemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343 , DOI: https://doi.org/10.46121/pspc.52.4.16

17.Dr.Ohmini Krishnamurthy Rajendran (Author), DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL DATA, Vol. 53 No. 4 (2025): October-December 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/327, DOI: https://doi.org/10.46121/pspc.53.4.33

18.Joshi, A. et al. (2023) 'Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis', npj Precision Oncology, 7(1), p. 28.

19.Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', npj Digital Medicine, 3(1), p. 136.

20.Dr.Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312 , DOI: https://doi.org/10.46121/pspc.52.4.13.

21.Dr.Rajatha Maradi Hemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8

22.Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.

23.Lambin,P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.

24.Chen,R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.

25.Chaudhary,K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.

26.Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.

27.Kather,J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.

28.Huang,S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.

29.Moor,M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.

30.Wei,L. et al. (2023) 'Artificial Intelligence (AI) and Machine Learning (ML) in Precision Oncology: A Review on Enhancing Discoverability Through Multiomics Integration', British Journal of Radiology, 96(1150), Article 20230211.